Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by juniper88on Dec 02, 2019 10:34am
72 Views
Post# 30413050

RE:RE:RE:RE:RE:RE:The new report is great, but...

RE:RE:RE:RE:RE:RE:The new report is great, but...I wasn't expecting a jump to $6 or anything like that, but we are down about 2.5% today!!  What good are these building blocks when the SP continues to slide and slide ??

Wino115 wrote: This is about building the audience and interest over time. It's not about a one time step up on sprewking.  It's a factual, in-depth report with models and sensible valuations that can now be picked up by anyone interested in learning about the company and will form their opinions from annual reports, credible analyst reports and their own model-building.  This is just one piece in the puzzle of beginning to build up credibility around the companies products and developments so some investors, not all, will be a little more confident about the case.  

It's just one -- but a desperately needed one. So don't overreact and expect a ton.  These are the building blocks and we need some more. Now Philippe at the conference tomorrow can tell anyone interested to go look at a newly issued in depth report.  

Building blocks for the audience people!  Don't be so short-term.


Bullboard Posts